Brokerages Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target at $9.40

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have earned a consensus rating of “Hold” from the six research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $9.40.

Several analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. Morgan Stanley set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th.

Insider Activity at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 220,000 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $4.20, for a total transaction of $924,000.00. Following the sale, the director owned 6,429,863 shares in the company, valued at approximately $27,005,424.60. This trade represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Ben R. Taylor sold 21,383 shares of the company’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $4.18, for a total value of $89,380.94. Following the completion of the transaction, the chief financial officer directly owned 761,550 shares of the company’s stock, valued at $3,183,279. The trade was a 2.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 805,786 shares of company stock worth $3,482,598 over the last three months. Company insiders own 8.43% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. TD Waterhouse Canada Inc. raised its position in shares of Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after buying an additional 2,200 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at about $31,000. Caitong International Asset Management Co. Ltd raised its holdings in Recursion Pharmaceuticals by 97.2% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after acquiring an additional 4,446 shares during the last quarter. Allworth Financial LP lifted its stake in Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after purchasing an additional 4,403 shares in the last quarter. Finally, Sequoia Financial Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $41,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Price Performance

RXRX opened at $3.98 on Thursday. The firm has a market capitalization of $2.07 billion, a PE ratio of -2.21 and a beta of 0.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.60 and a quick ratio of 4.60. The business’s 50-day moving average is $4.45 and its two-hundred day moving average is $4.92. Recursion Pharmaceuticals has a 1 year low of $3.54 and a 1 year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The firm had revenue of $5.18 million during the quarter, compared to analyst estimates of $19.36 million. During the same quarter in the prior year, the business posted ($0.34) EPS. The business’s revenue for the quarter was down 80.1% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.